Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1617)	9/13/2000 2:44:04 PM
From: SnowShredder	Respond to of 52153

Thanks...I was wondering why all of sudden there was action in ARIA. Best of luck, Where'd He Go?

To: tom pope who wrote (1617)	9/13/2000 3:51:40 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Tom, "efficient market" at work in the valuation of biotechs It's sort of understandable, actually. I myself haven't much of a clue as to what the valuation consequence of a patent announcement like ARIA's should be, so the average non-biotech investor certainly can't either. So the great-uninformed-masses (which in this case is just about everybody in the world) wait for some external validation. Briefing isn't much validation, but at least it's more than a company's own PR. It's no way to run a market, but it's the best we have. <g> Peter